N-[1-(1H-imidazol-4-yl)-3-oxo-4-methyl-2-pentyl]-2-methylpropanamide | 258260-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[1-(1H-imidazol-4-yl)-3-oxo-4-methyl-2-pentyl]-2-methylpropanamide
• 英文别名: N-[1-(1H-imidazol-5-yl)-4-methyl-3-oxopentan-2-yl]-2-methylpropanamide
• CAS: 258260-86-5
• 化学式: C₁₃H₂₁N₃O₂
• 分子量: 251.329
• InChiKey: PPHLXCRYWFOARH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[1-(1H-imidazol-4-yl)-3-oxo-4-methyl-2-pentyl]-2-methylpropanamide 在 盐酸 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 3.5h， 生成 N-[1-(1H-imidazol-5-yl)-4-methyl-3-oxopentan-2-yl]propanamide
  参考文献：
  名称：

  α₂ Adrenoceptor Agonists as Potential Analgesic Agents. 1. (Imidazolylmethyl)oxazoles and -thiazoles

  摘要：

  A series of (imidazolylmethyl)oxazoles and -thiazoles were prepared and evaluated as alpha(2) adrenoceptor agonists. These compounds were also tested in in vivo paradigms that are predictive of analgesic activity. Variations in both the imidazole and thiazole portions of the molecule were investigated. Some of the more potent compounds such as 22, 26, 45, and 53 displayed at receptor binding in the 10-20 nM range and also had significant, antinociceptive activity in the mouse abdominal irritant test (MAIT).

  DOI：

  10.1021/jm990005a
• 作为产物：
  描述：

  异丁酸酐 、 组氨酸甲酯 在 4-二甲氨基吡啶 、 isobutyric acid sodium salt 作用下， 反应 4.0h， 以38%的产率得到N-[1-(1H-imidazol-4-yl)-3-oxo-4-methyl-2-pentyl]-2-methylpropanamide
  参考文献：
  名称：

  α₂ Adrenoceptor Agonists as Potential Analgesic Agents. 1. (Imidazolylmethyl)oxazoles and -thiazoles

  摘要：

  A series of (imidazolylmethyl)oxazoles and -thiazoles were prepared and evaluated as alpha(2) adrenoceptor agonists. These compounds were also tested in in vivo paradigms that are predictive of analgesic activity. Variations in both the imidazole and thiazole portions of the molecule were investigated. Some of the more potent compounds such as 22, 26, 45, and 53 displayed at receptor binding in the 10-20 nM range and also had significant, antinociceptive activity in the mouse abdominal irritant test (MAIT).

  DOI：

  10.1021/jm990005a

文献信息

• REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
  申请人：Khvorova Anastasia

  公开号：US20130131141A1

  公开（公告）日：2013-05-23

  The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
• RNA INTERFERENCE IN OCULAR INDICATIONS
  申请人：Libertine Lyn

  公开号：US20130131142A1

  公开（公告）日：2013-05-23

  The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
• INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
  申请人：Khvorova Anastasia

  公开号：US20140113950A1

  公开（公告）日：2014-04-24

  The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
• METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
  申请人：RXI PHARMACEUTICALS CORPORATION

  公开号：US20160304875A1

  公开（公告）日：2016-10-20

  The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications. Aspects of the invention provide nucleic acid molecules for the prophylactic treatment of wounding to reduce scarring. Herein, it is demonstrated that a specific nucleic acid molecule, RXI-109 (targeting connective tissue growth factor (CTGF)), given prophylactically, reduces scarring during wound healing.
• METHODS FOR TREATING CANCER USING NUCLEIC ACIDS TARGETING MDM2 OR MYCN
  申请人：RXi Pharmaceuticals Corporation

  公开号：US20170051288A1

  公开（公告）日：2017-02-23

  Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.